CEA Report Reforming Biopharmaceutical Pricing Home Abroad Statements Releases Healthcare Issued February 9 2018 Council Economic AdvisersToday Council Economic Advisers CEA released report government help effectively reduce prices lifesaving drugs stimulating innovation pharmaceutical industry Please see executive summary read full report here.The affordability healthcare biopharmaceutical drugs top concern Americans It often asserted promoting innovation affordable drugs conflicting goals New innovations however often provide improved health previously available price obviate need costly care They thereby lower effective price health price patented drugs later price generic drugs Federal policies affect drug pricing satisfy two goals First domestic drug prices paid Americans reduced Second price better health future also reduced spurring medical innovation This report considers policy options simultaneously advance two seemingly conflicting goals.Reducing drug prices Americans pay means recognizing many artificially high prices result government policies prevent rather foster healthy price competition Drug prices example sometimes artificially high due government regulations raise prices This report discusses changes Medicare Medicaid programs could help lower domestic prices well reforms Food Drug Administration FDA could encourage robust price competition.Preserving incentives biopharmaceutical innovation achieved still promoting lower prices Americans Global financial returns product development drive innovation But returns unfairly low today This foreign governments primary buyers respective pharmaceutical markets force drug manufacturers comply pricing rules gain market access Through leverage foreign governments able set drug prices prevail United States erode returns innovation manufacturers might otherwise see selling markets Among members Organization Economic Co-operation Development OECD CEA estimates Americans pay 70 percent patented biopharmaceutical profits despite fact United States accounts 34 percent OECD GDP Purchasing Power Parity PPP In short pharmaceutical innovators—and foreign governments—across world rely America ’ patients taxpayers finance critical research development.The objective government biopharmaceutical policy ensure private sector competes invests meaningful innovations lower price health rather incentivizing market exclusivity high prices products The two goals reducing American prices stimulating innovation consistent achieved combined strategy corrects government policies hinder price-competition home time limiting free-riding abroad 